NASDAQ:CORT

Corcept Therapeutics News Headlines

$21.54
+0.01 (+0.05 %)
(As of 06/14/2021 03:02 PM ET)
Add
Compare
Today's Range
$21.53
$21.69
50-Day Range
$19.97
$24.31
52-Week Range
$12.20
$31.18
Volume12,447 shs
Average Volume561,603 shs
Market Capitalization$2.51 billion
P/E Ratio27.62
Dividend YieldN/A
Beta0.73

Corcept Therapeutics (NASDAQ CORT) News Headlines Today

SourceHeadline
TheStreet Lowers Corcept Therapeutics (NASDAQ:CORT) to C+TheStreet Lowers Corcept Therapeutics (NASDAQ:CORT) to C+
marketbeat.com - June 4 at 7:09 AM
Corcept Therapeutics Appoints Joshua M. Murray to Board of DirectorsCorcept Therapeutics Appoints Joshua M. Murray to Board of Directors
finance.yahoo.com - June 10 at 12:20 PM
Corcept Therapeutics Incorporated (NASDAQ:CORT) Not Lagging Market On Growth Or PricingCorcept Therapeutics Incorporated (NASDAQ:CORT) Not Lagging Market On Growth Or Pricing
nasdaq.com - May 19 at 12:25 PM
Corcepts (CORT) Lead Drug Korlym Aids Growth Amid CompetitionCorcept's (CORT) Lead Drug Korlym Aids Growth Amid Competition
finance.yahoo.com - May 14 at 2:11 PM
Corcepts (CORT) Q1 Earnings Miss Estimates, Revenues Fall Y/YCorcept's (CORT) Q1 Earnings Miss Estimates, Revenues Fall Y/Y
nasdaq.com - May 7 at 1:38 PM
Corcept Therapeutics (CORT) Misses Q1 Earnings and Revenue EstimatesCorcept Therapeutics (CORT) Misses Q1 Earnings and Revenue Estimates
finance.yahoo.com - May 6 at 10:36 PM
Addition of Relacorilant to Nab-Paclitaxel Improves Progression Free Survival (PFS) in Controlled, Phase 2 trial of 178 Patients with Platinum Resistant Ovarian CancerAddition of Relacorilant to Nab-Paclitaxel Improves Progression Free Survival (PFS) in Controlled, Phase 2 trial of 178 Patients with Platinum Resistant Ovarian Cancer
finance.yahoo.com - May 6 at 5:36 PM
Corcept Therapeutics Observes Large Reductions of Liver Fat and Transient Liver Enzyme Elevations in Phase 2 Trial of Miricorilant as a Potential Treatment for Patients with Nonalcoholic Steatohepatitis (NASH)Corcept Therapeutics Observes Large Reductions of Liver Fat and Transient Liver Enzyme Elevations in Phase 2 Trial of Miricorilant as a Potential Treatment for Patients with Nonalcoholic Steatohepatitis (NASH)
finance.yahoo.com - May 6 at 5:36 PM
Corcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial ResultsCorcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial Results
finance.yahoo.com - May 6 at 5:36 PM
Corcept Therapeutics Stock Is Believed To Be Modestly OvervaluedCorcept Therapeutics Stock Is Believed To Be Modestly Overvalued
ca.finance.yahoo.com - May 5 at 9:34 PM
Corcept Therapeutics (CORT) Sees Hammer Chart Pattern: Time to Buy?Corcept Therapeutics (CORT) Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - May 5 at 11:33 AM
CORT Crosses Below Key Moving Average LevelCORT Crosses Below Key Moving Average Level
nasdaq.com - May 4 at 2:06 PM
Earnings Preview: Corcept Therapeutics (CORT) Q1 Earnings Expected to DeclineEarnings Preview: Corcept Therapeutics (CORT) Q1 Earnings Expected to Decline
finance.yahoo.com - April 26 at 1:55 PM
Imagine Holding Corcept Therapeutics (NASDAQ:CORT) Shares While The Price Zoomed 398% HigherImagine Holding Corcept Therapeutics (NASDAQ:CORT) Shares While The Price Zoomed 398% Higher
finance.yahoo.com - April 5 at 8:06 AM
Why Is Corcept (CORT) Down 11.1% Since Last Earnings Report?Why Is Corcept (CORT) Down 11.1% Since Last Earnings Report?
finance.yahoo.com - March 25 at 12:29 PM
Corcept (CORT) Begins Adrenal Cancer Study on RelacorilantCorcept (CORT) Begins Adrenal Cancer Study on Relacorilant
finance.yahoo.com - March 16 at 1:45 PM
Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in Patients with Adrenal Cancer with Cortisol ExcessCorcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in Patients with Adrenal Cancer with Cortisol Excess
finance.yahoo.com - March 15 at 7:35 AM
Corcept Therapeutics Expands Executive Team; Atabak Mokari Joins As Chief Financial Officer; Charles Robb Named Chief Business OfficerCorcept Therapeutics Expands Executive Team; Atabak Mokari Joins As Chief Financial Officer; Charles Robb Named Chief Business Officer
finance.yahoo.com - March 1 at 8:00 PM
Corcept (CORT) Q4 Earnings In Line, Revenues Miss EstimatesCorcept (CORT) Q4 Earnings In Line, Revenues Miss Estimates
nasdaq.com - February 24 at 1:44 PM
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2020 Audited Financial ResultsCorcept Therapeutics Announces Fourth Quarter and Full-Year 2020 Audited Financial Results
finance.yahoo.com - February 23 at 7:32 PM
Trade Alert: The CFO & Secretary Of Corcept Therapeutics Incorporated (NASDAQ:CORT), Gary Robb, Has Sold Some Shares RecentlyTrade Alert: The CFO & Secretary Of Corcept Therapeutics Incorporated (NASDAQ:CORT), Gary Robb, Has Sold Some Shares Recently
nasdaq.com - February 21 at 8:55 AM
Corcept Therapeutics Incorporateds (NASDAQ:CORT) Stock Is Going Strong: Is the Market Following Fundamentals?Corcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Is Going Strong: Is the Market Following Fundamentals?
finance.yahoo.com - February 19 at 8:02 AM
Corcept Therapeutics (CORT) CEO Joseph Belanoff on Q4 2020 Results - Earnings Call TranscriptCorcept Therapeutics' (CORT) CEO Joseph Belanoff on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - February 10 at 5:47 PM
AMRX or CORT: Which Is the Better Value Stock Right Now?AMRX or CORT: Which Is the Better Value Stock Right Now?
finance.yahoo.com - February 10 at 12:42 PM
Corcept (CORT) Posts Preliminary 20 Results, Gives 2021 ViewCorcept (CORT) Posts Preliminary '20 Results, Gives 2021 View
finance.yahoo.com - February 9 at 3:14 PM
Corcept Therapeutics Incorporated (CORT) Q4 2020 Earnings Call TranscriptCorcept Therapeutics Incorporated (CORT) Q4 2020 Earnings Call Transcript
fool.com - February 8 at 11:14 PM
Corcept Therapeutics, Inc. to Host Earnings CallCorcept Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - February 8 at 6:17 PM
Corcept Therapeutics Announces Fourth Quarter, Full-Year 2020 Preliminary Selected Financial Results and 2021 Revenue Guidance; Provides Corporate UpdateCorcept Therapeutics Announces Fourth Quarter, Full-Year 2020 Preliminary Selected Financial Results and 2021 Revenue Guidance; Provides Corporate Update
finance.yahoo.com - February 8 at 6:17 PM
Why Corcept Therapeutics (CORT) Might Surprise This Earnings SeasonWhy Corcept Therapeutics (CORT) Might Surprise This Earnings Season
finance.yahoo.com - February 5 at 12:48 PM
Corcept Therapeutics to Announce Preliminary Selected Financial Results, Provide Corporate Update and Host Conference CallCorcept Therapeutics to Announce Preliminary Selected Financial Results, Provide Corporate Update and Host Conference Call
finance.yahoo.com - February 1 at 6:38 PM
CORT Jan 2023 20.000 putCORT Jan 2023 20.000 put
au.finance.yahoo.com - January 30 at 8:37 AM
CORT May 2021 28.000 putCORT May 2021 28.000 put
au.finance.yahoo.com - January 29 at 7:09 PM
CORT Jan 2022 40.000 callCORT Jan 2022 40.000 call
au.finance.yahoo.com - January 29 at 7:09 PM
CORT Feb 2021 28.000 putCORT Feb 2021 28.000 put
au.finance.yahoo.com - January 28 at 12:14 AM
Heres What Corcept Therapeutics Incorporateds (NASDAQ:CORT) Shareholder Ownership Structure Looks LikeHere's What Corcept Therapeutics Incorporated's (NASDAQ:CORT) Shareholder Ownership Structure Looks Like
finance.yahoo.com - January 20 at 9:52 AM
Corcept (CORT) Up More Than 50% in Past 3 Months: Heres WhyCorcept (CORT) Up More Than 50% in Past 3 Months: Here's Why
finance.yahoo.com - December 31 at 2:59 PM
What Can We Make Of Corcept Therapeutics (NASDAQ:CORT) CEO Compensation?What Can We Make Of Corcept Therapeutics' (NASDAQ:CORT) CEO Compensation?
finance.yahoo.com - December 21 at 9:08 AM
Is CORT A Good Stock To Buy According To Hedge Funds?Is CORT A Good Stock To Buy According To Hedge Funds?
finance.yahoo.com - December 19 at 7:52 PM
First Week of CORT August 2021 Options TradingFirst Week of CORT August 2021 Options Trading
nasdaq.com - December 18 at 1:53 PM
Why Is Corcept (CORT) Up 25.8% Since Last Earnings Report?Why Is Corcept (CORT) Up 25.8% Since Last Earnings Report?
finance.yahoo.com - December 3 at 3:21 PM
Corcept Therapeutics Appoints Gillian M. Cannon, PhD, to Board of DirectorsCorcept Therapeutics Appoints Gillian M. Cannon, PhD, to Board of Directors
markets.businessinsider.com - November 23 at 5:10 PM
Forecast: Analysts Think Corcept Therapeutics Incorporateds (NASDAQ:CORT) Business Prospects Have Improved DrasticallyForecast: Analysts Think Corcept Therapeutics Incorporated's (NASDAQ:CORT) Business Prospects Have Improved Drastically
nasdaq.com - November 21 at 9:22 AM
Why Corcepts Stock Is Trading Higher TodayWhy Corcept's Stock Is Trading Higher Today
benzinga.com - November 20 at 8:51 AM
U.S. Patent Trial and Appeals Board Affirms Validity of All Claims of Corcepts U.S. Patent No.10,195,214U.S. Patent Trial and Appeals Board Affirms Validity of All Claims of Corcept's U.S. Patent No.10,195,214
marketwatch.com - November 19 at 2:36 PM
CORT Dec 2020 11.000 putCORT Dec 2020 11.000 put
au.finance.yahoo.com - November 18 at 11:22 PM
CORT Jan 2023 10.000 putCORT Jan 2023 10.000 put
au.finance.yahoo.com - November 18 at 11:22 PM
U.S. Patent Trial and Appeals Board Affirms Validity of All Claims of Corcept’s U.S. Patent No.10,195,214U.S. Patent Trial and Appeals Board Affirms Validity of All Claims of Corcept’s U.S. Patent No.10,195,214
finance.yahoo.com - November 18 at 6:22 PM
Independent Director George Baker Just Bought A Handful Of Shares In Corcept Therapeutics Incorporated (NASDAQ:CORT)Independent Director George Baker Just Bought A Handful Of Shares In Corcept Therapeutics Incorporated (NASDAQ:CORT)
nasdaq.com - November 13 at 8:03 AM
George Baker Is The Independent Director of Corcept Therapeutics Incorporated (NASDAQ:CORT) And Just Spent US$243k On SharesGeorge Baker Is The Independent Director of Corcept Therapeutics Incorporated (NASDAQ:CORT) And Just Spent US$243k On Shares
finance.yahoo.com - November 13 at 8:03 AM
Noteworthy Wednesday Option Activity: FPRX, DDOG, CORTNoteworthy Wednesday Option Activity: FPRX, DDOG, CORT
nasdaq.com - November 11 at 8:53 PM
Wednesday 11/11 Insider Buying Report: AIZ, CORTWednesday 11/11 Insider Buying Report: AIZ, CORT
nasdaq.com - November 11 at 3:52 PM
This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.